| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Neurokinin-1 (NK1) receptor (selective antagonist). FK-888 competitively antagonizes the NK1 receptor, blocking substance P binding and downstream signaling. It exhibits high selectivity for NK1 over NK2 and NK3 receptors. The dipeptide structure confers metabolic stability and high affinity.
|
|---|---|
| ln Vitro |
FK-888 displaces [³H]-substance P binding with Ki values of 0.69 nM and 0.45 μM in different assay systems. It inhibits substance P-induced signaling pathways, including phosphatidylinositol turnover and calcium mobilization, in NK1 receptor-expressing cells. The compound demonstrates potent antagonism of NK1 receptor-mediated smooth muscle contraction and plasma protein extravasation in vitro.
|
| ln Vivo |
In vivo, FK-888 inhibits substance P-induced plasma extravasation and inflammatory responses in animal models. It has been evaluated for analgesic and anti-inflammatory effects in preclinical studies. The compound's high selectivity and potency make it a valuable tool for dissecting NK1 receptor functions in pain transmission, neurogenic inflammation, and airway disease models.
|
| Enzyme Assay |
Radioligand binding assay: Membranes from NK1 receptor-expressing tissues (e.g., guinea pig lung, rat brain) or recombinant cells are incubated with [³H]-substance P and varying concentrations of FK-888. Non-specific binding is determined with excess unlabeled substance P. Reactions are terminated by filtration, and radioactivity counted. Ki values are calculated by Cheng-Prusoff equation. Selectivity is assessed against NK2 and NK3 receptors.
|
| Cell Assay |
NK1 receptor-mediated calcium mobilization assay: Cells expressing recombinant NK1 receptors are loaded with a fluorescent calcium indicator (e.g., Fura-2 or Fluo-4). Substance P is added to stimulate calcium release. FK-888 is pre-incubated at varying concentrations. Fluorescence is monitored using a spectrofluorometer or microplate reader. IC₅₀ values are determined from dose-response curves.
|
| Animal Protocol |
In vivo neurogenic inflammation model: Rats or mice are anesthetized, and substance P or capsaicin is injected intradermally to induce plasma protein extravasation. FK-888 is administered intravenously or topically. Extravasation is quantified by Evans blue dye leakage. In pain models, FK-888 is administered intrathecally or systemically, and nociceptive responses to thermal or mechanical stimuli are assessed.
|
| References | |
| Additional Infomation |
(2S,4R)-4-hydroxy-1-[(1-methyl-3-indolyl)-oxymethyl]-N-[(2S)-1-[methyl-(phenylmethyl)amino]-3-(2-naphthyl)-1-oxopropane-2-yl]-2-pyrrolidinecarboxamide is a peptide.
|
| Molecular Formula |
C36H36N4O4
|
|---|---|
| Molecular Weight |
588.71
|
| Exact Mass |
588.274
|
| CAS # |
138449-07-7
|
| PubChem CID |
107967
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.26g/cm3
|
| Boiling Point |
901.9ºC at 760mmHg
|
| Flash Point |
499.2ºC
|
| Vapour Pressure |
5.08E-35mmHg at 25°C
|
| Index of Refraction |
1.658
|
| LogP |
4.621
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
44
|
| Complexity |
1020
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
OC1CN(C(C2C3C(=CC=CC=3)N(C)C=2)=O)C(C(NC(C(N(C)CC2C=CC=CC=2)=O)CC2C=CC3C(=CC=CC=3)C=2)=O)C1
|
| InChi Key |
BFNKQTIJVFGCKQ-PDJGWCFMSA-N
|
| InChi Code |
InChI=1S/C36H36N4O4/c1-38-23-30(29-14-8-9-15-32(29)38)35(43)40-22-28(41)20-33(40)34(42)37-31(36(44)39(2)21-24-10-4-3-5-11-24)19-25-16-17-26-12-6-7-13-27(26)18-25/h3-18,23,28,31,33,41H,19-22H2,1-2H3,(H,37,42)/t28-,31+,33+/m1/s1
|
| Chemical Name |
(2S,4R)-N-[(2S)-1-[benzyl(methyl)amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]-4-hydroxy-1-(1-methylindole-3-carbonyl)pyrrolidine-2-carboxamide
|
| Synonyms |
FK888; FK 888; FK-888
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6986 mL | 8.4931 mL | 16.9863 mL | |
| 5 mM | 0.3397 mL | 1.6986 mL | 3.3973 mL | |
| 10 mM | 0.1699 mL | 0.8493 mL | 1.6986 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
